34.46

4.38% -1.58

After Hours: 33.67 -0.79 -2.29%

First Tracks Biotherapeutics Inc (TRAX)

Overview News Price History Option Chain Financials Discussions Forecast

First Tracks Biotherapeutics Inc stock is traded at $34.46, with a volume of 1.04M. It is down -4.38% in the last 24 hours and down -11.64% over the past month. First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Previous Close:

$36.04

Open:

$37.07

24h Volume:

1.04M

Relative Volume:

0.65

Market Cap:

$1.23B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+8.19%

1M Performance:

-11.64%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$33.38

$37.24

1-Week Range:

$30.88

$40.50

52-Week Range:

$14.72

$49.91

First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile

Name

First Tracks Biotherapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

212-373-3000

Address

10770 WATERIDGE CIRCLE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

TRAX's Discussions on Twitter

Compare TRAX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAX First Tracks Biotherapeutics Inc	34.46	1.23B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-26	Initiated	Canaccord Genuity	Buy
Sep-18-26	Initiated	Evercore ISI	Outperform
Sep-16-26	Initiated	Guggenheim	Buy
Aug-18-26	Initiated	Wolfe Research	Outperform
Jun-08-26	Initiated	Wells Fargo	Overweight
May-04-26	Initiated	Piper Sandler	Overweight
Apr-28-26	Initiated	H.C. Wainwright	Buy
Apr-24-26	Initiated	Leerink Partners	Outperform
Apr-24-26	Initiated	Wedbush	Outperform
Apr-23-26	Initiated	JP Morgan	Overweight
Apr-22-26	Initiated	Barclays	Overweight
Apr-21-26	Initiated	UBS	Buy

View All

First Tracks Biotherapeutics Inc Stock (TRAX) Latest News

Oct 15, 2026

First Tracks Biotherapeutics raises $200 million in private placement at $32.75 per share - Minichart

Oct 15, 2026

First Tracks Biotherapeutics Secures $200 Million Private Placement at $32.75 Per Share - TradingView

Oct 15, 2026

First Tracks Biotherapeutics Targets About $200 Million in Placement - TOKENPOST

Oct 15, 2026

First Tracks Biotherapeutics Announces $200 Million Private Placement - GlobeNewswire

Oct 15, 2026

Oct 13, 2026

First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data - Yahoo Finance

Oct 13, 2026

Oct 12, 2026

Breaking News about First Tracks Biotherapeutics, Inc.Ordinary Shares (Nasdaq:TRAX) - FinancialContent

Oct 12, 2026

Oct 09, 2026

Markets & StocksFirst Tracks Biotherapeutics, Inc.Ordinary Shares (Nasdaq:TRAX) Stock Quote - FinancialContent

Oct 09, 2026

Sep 18, 2026